Dynamic Tension between Pharmaceuticals, Consumers, and Media & Controlling AI with Equivalent Governance
Monday, December 4, 2023
The New York Academy of Sciences
Welcome and Introductions: 11:30 am to 11:45 am
Initial Presentation: 11:45 am to 12:45 pm
Speaker: Dawn S. Talbot
Topic: Controlling AI with Equivalent Governance Standards and Controls for both Human and Digital Beings
Following the release of ChatGPT on November 22, 2022, the need to control or better control AI has become a widespread public and professional goal. Our speaker has worked conceptually and operationally to develop governance systems and their standards and controls. This has been within an elegant and general planning framework that applies standards equivalently to both semi-autonomous (imbedded AI) systems and human processes (traditional procedures). She has also devised a mixed-mathematics approach for filtering the actions of an AI or human process to detect violations of control standards.
Public access to Artificial Intelligence (“AI”) may accelerate the spread of semi- and fully-autonomous organizations and governmental units that deploy AI agents (“digital beings”). Yet, current management techniques may prove outdated and autonomous governance policies are nascent.
This talk is focused on the governance of semi-autonomous decentralized finance systems (“De-Fi”). It presents a case study of a traditional financial self-governance method where a combinatorial word problem was discovered buried in untagged, jargon-encoded policies. The research suggests De-Fi systems may have based their design upon an inaccurate rendition of a traditional financial system. To identify similar patterns, a six-step methodology is proposed which draws upon practices in social science, combinatorics, fractal geometry, and quantum physics. The research is intended to aid in the design of dual use self-governance policies, equally applicable to human and digital beings. It may also thwart the use of potential loopholes for digital beings violating legislation and regulations.
Dawn S. Talbot is lead co-author of “Redefining the Future of the Economy: Governance Blocks and Economic Architecture,” 2020. As a Wall Street emerging technologies specialist, Dawn served as institutional research analyst, corporate finance professional, and portfolio manager. She advised sovereign, pension, mutual and endowment funds using financial modeling, investment vehicle design, risk simulation, and portfolio optimization. She later advised tech startups. She helped establish blockchain and artificial intelligence innovation labs. Her early technology background included systems design, protocol design and rapid prototyping for Fortune 500 firms, as well as user interface design for senior officers at one US Air Force base. Her master’s thesis dealt with configuration complexity by proposing a dynamic optimization method for globally distributed but privately managed servers. Ms. Talbot is currently focused on methods of encoding accountability in semi-autonomous systems. She holds an M.S. in Information Systems Engineering from Brooklyn Polytechnic University and a B.S. in Business from Pennsylvania State University.
Main Presentation: 12:45 pm to 2:30 pm
Speaker: Clif Hotvedt
Topic: Consumer Expectations and the Dynamic Tension between the Pharmaceutical Industry, Consumers, and "the Media”
While always vitally important, as the financial stakes have grown exponentially higher, pharmaceutical, biological, and medical device patents and their granting, maintenance, and extension have escalated in importance. This presentation will briefly consider the meaning of patents, what they cover and for how long and how the life of a product may be extended through strategic management of all the regulatory nuances of the Food and Drug Administration regulations. At the same time, attention will be paid to the downstream effects of inhibiting product improvements, as well as to payers, whether health plans or individuals, of delays in availability of products after patent expiration.
Clif Hotvedt's diverse scientific background reflects his experience in the pharmaceutical industry, as a medical writer in the regulatory and clinical affairs departments of Ives Laboratories and at leading public relations firms including Robert Marston & Associates, Manning Selvage & Lee, and Ketchum, where he served as vice president and global director of medical & scientific affairs. For 46 years, he has counseled companies on over 100 small molecule drugs, biologicals and devices for indications including cardiovascular disease, rheumatology, metabolic disease, dermatology, central nervous system disease, vaccines, infectious disease, and cancer.
A New Mexico State University graduate in secondary education and journalism, Clif continues to use his teaching background to develop and present courses on the FDA approval process, pharmacokinetics, pharmacodynamics, and biostatistics among other topics for coworkers and clients. Clif is a member of the Lyceum Society and has been a frequent presenter at our meetings. His previous topics have included: “The FDA Drug Approval Process”(November 2015); “How the new PCSK9 Cholesterol-Lowering Drugs work” (May 2016); “How to read a Drug Label” (April 2017); “Biosimilars: the New ‘Generics’?(June 2018); “The Human Microbiome” (May 2019); "Drug Pricing" (June 2020); “Artificial Intelligence (AI) and Health Care” (October 2020); "Drug Pricing Revisited" (November 2020); and “The Nobel Prize in Physiology or Medicine 2022” (December 2022).